Regulatory FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia FDAThe U.S.NeuroscienceRead full story pharminent April 30, 2026 (Last updated: May 1, 2026) FDA The U.S. Neuroscience Read full story Post navigation Previous: Eligibility for Medicare Savings Programs for Specified Low-Income Medicare Beneficiaries (SLMBs)Next: Two biotechs raise a combined $556M in latest spurt of IPOs Related Stories Regulatory FDA’s ODAC delivers one loss, one win for AstraZeneca pharminent May 1, 2026 Regulatory Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation pharminent May 1, 2026 Regulatory UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy pharminent April 30, 2026
